<DOC>
	<DOCNO>NCT01467921</DOCNO>
	<brief_summary>Oxaliplatin platinum analogue significant antitumor activity well tolerability cisplatin . The objective study evaluate safety activity leucovorin 5-fluorouracil leucovorin 5-fluorouracil plus oxaliplatin combination chemotherapy give adjuvant therapy curatively-resected , node-positive esophageal cancer .</brief_summary>
	<brief_title>Study LV5FU2 Versus FOLFOX Curatively-resected , Node-positive Esophageal Squamous Cell Carcinoma</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma , Squamous Cell</mesh_term>
	<mesh_term>Esophageal Neoplasms</mesh_term>
	<mesh_term>Oxaliplatin</mesh_term>
	<mesh_term>Fluorouracil</mesh_term>
	<criteria>Aged 20 year old Histologically confirm squamous cell carcinoma esophagus Curatively ( R0 ) resect , lymph node positive ECOG performance status 0 1 Restoration oral intake &gt; 1500 kcal/d No prior chemotherapy except neoadjuvant one No prior radiotherapy within 1 month registration Adequate marrow , hepatic , renal cardiac function Provision sign write informed consent Severe comorbid illness and/or active infection Prior treatment oxaliplatin Pregnant lactate woman Active CNS metastases controllable radiotherapy corticosteroid Known history hypersensitivity study drug</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2011</verification_date>
</DOC>